| Primary |
| Hypertension |
16.2% |
| Prophylaxis |
7.6% |
| Depression |
6.9% |
| Arthralgia |
6.6% |
| Cholecystitis |
5.5% |
| Essential Hypertension |
5.5% |
| Gastrooesophageal Reflux Disease |
4.8% |
| Product Used For Unknown Indication |
4.8% |
| Rheumatoid Arthritis |
4.8% |
| Endocarditis |
4.1% |
| Diabetes Mellitus |
3.8% |
| Diabetic Foot |
3.8% |
| Osteoporosis |
3.8% |
| Hypercholesterolaemia |
3.4% |
| Staphylococcal Infection |
3.4% |
| Dermatomyositis |
3.1% |
| Gastric Ulcer |
3.1% |
| Respiratory Disorder |
3.1% |
| Abdominal Pain Upper |
2.8% |
| Atrial Flutter |
2.8% |
|
| Hyponatraemia |
12.4% |
| Renal Failure Acute |
11.7% |
| Thrombocytopenia |
10.9% |
| Toxic Skin Eruption |
6.6% |
| Vomiting |
5.8% |
| Pancytopenia |
5.1% |
| Pyrexia |
5.1% |
| Renal Failure |
5.1% |
| Thrombocytopenic Purpura |
5.1% |
| Weight Decreased |
4.4% |
| Agranulocytosis |
3.6% |
| Neutropenia |
3.6% |
| Inappropriate Antidiuretic Hormone Secretion |
2.9% |
| Rash Papular |
2.9% |
| Septic Shock |
2.9% |
| Vertigo |
2.9% |
| Anaemia Haemolytic Autoimmune |
2.2% |
| Bone Marrow Failure |
2.2% |
| Cataract |
2.2% |
| International Normalised Ratio Increased |
2.2% |
|
| Secondary |
| Drug Use For Unknown Indication |
46.9% |
| Product Used For Unknown Indication |
14.8% |
| Hypertension |
6.5% |
| Arthralgia |
2.7% |
| Helicobacter Infection |
2.6% |
| Prophylaxis |
2.4% |
| Diabetic Foot |
2.3% |
| Ill-defined Disorder |
2.2% |
| Pain |
2.2% |
| Congestive Cardiomyopathy |
2.0% |
| Anxiety |
1.9% |
| Depression |
1.7% |
| Gastrooesophageal Reflux Disease |
1.7% |
| Cardiac Failure |
1.5% |
| Cholecystitis |
1.5% |
| Diabetes Mellitus |
1.5% |
| Parkinson's Disease |
1.5% |
| Oesophagitis |
1.4% |
| Abdominal Pain Upper |
1.3% |
| Hypercholesterolaemia |
1.3% |
|
| Thrombocytopenia |
17.8% |
| Toxic Epidermal Necrolysis |
9.1% |
| Hyponatraemia |
7.1% |
| Renal Failure Acute |
7.1% |
| Tumour Lysis Syndrome |
6.6% |
| Vertigo |
6.1% |
| Vomiting |
6.1% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
4.6% |
| Pancreatitis Acute |
4.6% |
| Cytolytic Hepatitis |
4.1% |
| Renal Failure Chronic |
3.6% |
| Pancytopenia |
3.0% |
| Weight Decreased |
3.0% |
| Agranulocytosis |
2.5% |
| Myalgia |
2.5% |
| Neutropenia |
2.5% |
| Pancreatitis |
2.5% |
| Pupils Unequal |
2.5% |
| Septic Shock |
2.5% |
| Hepatic Neoplasm Malignant |
2.0% |
|
| Concomitant |
| Drug Use For Unknown Indication |
37.6% |
| Product Used For Unknown Indication |
14.1% |
| Hypertension |
5.9% |
| Prophylaxis |
5.1% |
| Unevaluable Event |
4.1% |
| Pain |
4.0% |
| Rheumatoid Arthritis |
4.0% |
| Depression |
3.0% |
| Thrombosis Prophylaxis |
2.6% |
| Gastric Cancer |
2.3% |
| Multiple Myeloma |
2.0% |
| Renal Transplant |
2.0% |
| Anxiety |
1.9% |
| Premedication |
1.9% |
| Hiv Infection |
1.8% |
| Sepsis |
1.7% |
| Asthma |
1.5% |
| Type 2 Diabetes Mellitus |
1.5% |
| Atrial Fibrillation |
1.4% |
| Diabetes Mellitus |
1.4% |
|
| Renal Failure Acute |
14.2% |
| Thrombocytopenia |
9.1% |
| Vomiting |
8.5% |
| Renal Failure |
6.8% |
| General Physical Health Deterioration |
6.6% |
| Toxic Skin Eruption |
5.1% |
| Pyrexia |
4.6% |
| Weight Decreased |
4.6% |
| International Normalised Ratio Increased |
4.3% |
| Septic Shock |
4.3% |
| Transplant Rejection |
4.3% |
| Neutropenia |
3.7% |
| Rhabdomyolysis |
3.4% |
| Somnolence |
3.4% |
| Cytolytic Hepatitis |
3.1% |
| Urinary Retention |
3.1% |
| Loss Of Consciousness |
2.8% |
| Sepsis |
2.8% |
| Pancytopenia |
2.6% |
| Subdural Haematoma |
2.6% |
|
| Interacting |
| Product Used For Unknown Indication |
45.0% |
| Gastric Haemorrhage |
16.3% |
| Prophylaxis |
12.5% |
| Essential Hypertension |
6.3% |
| Pruritus |
6.3% |
| Bronchitis |
5.0% |
| Constipation |
5.0% |
| Gastric Ulcer |
2.5% |
| Duodenal Ulcer |
1.3% |
|
| Skin Necrosis |
29.4% |
| Drug Interaction |
17.6% |
| Respiratory Distress |
17.6% |
| Haematuria |
11.8% |
| Hyponatraemia |
5.9% |
| International Normalised Ratio Increased |
5.9% |
| Thrombocytopenia |
5.9% |
| Urticaria |
5.9% |
|
